| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | Q2 +43% YoY, H1 +25%; includes ₹53 Cr one-time milestone revenue. |
|---|---|
| Margins | API gross margin steady above 60%; API EBITDA margin stable near 30%. |
| Order book | Take-or-pay capacity contracted; contract values withheld for confidentiality. |
| Demand visibility | Claims strong traction in biomanufacturing; no quantified demand data disclosed. |
| Management confidence | Over-optimistic; defers specifics on pricing, Premarin, and capacity numbers. |
Growth
Q2 revenue +43% YoY, but ₹53 Cr one-time milestone inflates it. API +16%, volume-led, the organic core.
Outlook
FY27 guidance maintained: ~20% revenue growth, ~25% EBITDA growth, ±5ppt. Annual capex ₹200–300 Cr.
Risks
Milestone-driven revenue is lumpy; receivables jumped to ₹268 Cr; API price pressure; US approval slipping to late CY27.
Last quarter's promises, checked
Delivered
- Guided API growth high-single-digit → Q2 API +16%, H1 +11% (= BEAT)
- Guided H2 milestones to offset ₹23Cr/qtr new-biz opex → ₹53Cr DCV milestone booked in Q2 (= BEAT)
- Guided API gross margin 60%+ → above 60% (= BEAT)
Partly delivered
- Guided FY27 revenue ~20%, EBITDA ~25% (±5ppt) → H1 revenue +25% incl. ₹53Cr one-time (= PARTIAL)
- Guided capex ₹200–250Cr/yr → plan now ₹200–300Cr; H1 spend ₹113Cr (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: SYMBIOTEC. Summary written with AI assistance from the document.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,525.80
- Market cap
- ₹9,804 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Results Update
Symbiotec Pharmalab released its Q2 and H1 FY27 investor release, reporting consolidated Q2 revenue of ₹280 crore and PAT of ₹52 crore. The release also cites a ₹53 crore milestone revenue from a US licensing agreement.
Symbiotec Pharmalab Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹280 Cr (+43%), PAT ₹52 Cr (+169%); H1 revenue ₹498 Cr (+25%), PAT ₹66 Cr (+34%). Capex-led push into DCV injectables and CDMO.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing lists promoter and public holdings with no transaction or corporate event.
Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab schedules a 5 November 2026 board meeting to consider unaudited quarterly and half-year results. No amounts are proposed.
Symbiotec Pharmalab Share Pledge
Promoters of Symbiotec Pharmalab submitted a revised disclosure to update the lender and trustee names for their pledged share encumbrance.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31 of the SEBI LODR Regulations.